問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

210Cases

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2021-04-01 - 2022-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-06-01 - 2019-12-31

Phase III

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

  • Condition/Disease

    Open-angle Glaucoma or Ocular Hypertension

  • Test Drug

    bimatoprost SR/implant

Participate Sites
4Sites

Terminated4Sites

2013-08-01 - 2020-06-30

Phase III

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

  • Condition/Disease

    HER2+ Metastatic Breast Cancer(MBC)

  • Test Drug

    Neratinib

Participate Sites
16Sites

Terminated16Sites

2021-12-01 - 2024-07-29

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis

  • Condition/Disease

    Generalized Myasthenia Gravis Myasthenia Gravis

  • Test Drug

    ALXN2050

Participate Sites
3Sites

Recruiting3Sites

2022-03-31 - 2023-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Terminated2Sites

2023-12-01 - 2029-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    BION-1301

Participate Sites
8Sites

Not yet recruiting8Sites

2020-11-19 - 2024-12-31

Phase III

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

  • Condition/Disease

    Chronic Kidney Disease With Metabolic Acidosis

  • Test Drug

    TRC101

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

2022-10-05 - 2024-02-12

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

  • Condition/Disease

    TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

1 12 13 14 15 16 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB